Key Takeaways: Digital Therapeutics Explained: When Software Becomes Treatment
- The category is important because software can scale care that is otherwise hard to access.
- Some products use clinical language without being evaluated as treatments.
- Good digital therapeutics are studied for a specific population and outcome.
Table of Contents
- What a patient should know before starting
- Not every wellness app is a therapeutic
- Look beyond the word clinical
- Evidence and intended use define the category
- The program should fit the patient’s real life
- Therapeutic data can become part of a health record
- Questions about cost, access and follow-up
- A couple of practical questions
- management software should come with a management pathway
- Software becomes management only with boundaries
- What separates one from an app
Digital therapeutics are not ordinary wellness apps with better branding. In the strict sense, they are software-based interventions designed to prevent, manage or manage a defined condition, often with clinical evidence and sometimes regulatory clearance. That distinction matters because a breathing app that says it helps relaxation is very different from software prescribed as part of management for insomnia, ADHD or substance use disorder.
The examples below are educational rather than personalized informational context. Product availability and authorised features related to digital therapeutics explained can vary by country and may change over time.
With digital therapeutics explained, the practical question is not whether the technology is advanced. It is whether software as a medical device and evidence-based intervention are measured well enough to support a safe next step.
What a patient should know before starting
- Look for the medical condition the product is intended to address.
- Check whether clinical trials were published and who funded them.
- Ask whether a prescription or clinician supervision is required.
- Understand the data collected during use.
- Clarify cost, insurance coverage and what happens after the program ends.
Not every wellness app is a therapeutic
The category is important because software can scale care that is otherwise hard to access. A structured CBT-I program for insomnia, for example, can deliver lessons and exercises without requiring weekly in-person sessions. But software also faces a practical problem: management only works if users complete it, clinicians trust it and insurers or patients are willing to pay for it.
Look beyond the word clinical
Some products use clinical language without being evaluated as treatments. Check the exact intended use, the group studied and the outcome measured. A trial showing better engagement is not the same as a trial showing meaningful symptom improvement. Likewise, an intervention tested alongside usual care should not be presented as a replacement for that care.
Digital therapeutics may include structured lessons, monitoring, reminders and feedback over several weeks. The work can still be demanding. A patient needs to know how often the program is used, what happens after missed sessions and whether a clinician can see progress or respond to deterioration.
- Ask whether the product is regulated for its stated purpose.
- Check whether access requires a prescription or clinician referral.
- Find out what support is available when the program is difficult to use.
- Review data retention before entering symptom or management information.
Evidence and intended use define the category
Good digital therapeutics are studied for a specific population and outcome. They should explain who they are for, how long management lasts, what data is collected and what evidence supports the claim. Regulatory status can add confidence, but it does not guarantee that every patient will benefit or that the product will be easy to use.
The program should fit the patient’s real life
A therapeutic may be evidence-based and still be difficult to complete. Reading level, language, disability access, internet reliability and time demands all influence whether the intervention can work outside a trial.
Good design includes reminders that can be adjusted, clear progress information and support when a user falls behind. Blaming the patient for poor engagement ignores the responsibility of the product and care pathway.
Therapeutic data can become part of a health record
Data created through digital therapeutics explained deserves a stronger standard than ordinary app activity. Protect reports involving software as a medical device or evidence-based intervention with secure accounts and share only what a clinician or trusted carer needs.
Questions about cost, access and follow-up
Patients should manage a digital therapeutic the way they would manage any other therapy: ask what it is meant to do, what evidence supports it, what side effects or risks are possible, and who will monitor progress. The most promising use is not replacing clinicians, but extending structured care between appointments.
A couple of practical questions
Is a digital therapeutic the same as a wellness app?
No. A therapeutic is designed for a specific clinical purpose and should have evidence and oversight appropriate to that claim.
Can it replace medication or therapy?
Only when a qualified clinician and the product’s approved or supported use indicate that approach. Many products are designed to complement existing care.
management software should come with a management pathway
A digital therapeutic is more credible when the intended condition, user group, program length, clinician role and expected outcome are specific. The reader should also know what happens if symptoms worsen or the program is not completed.
Access often depends on country, prescription rules, insurance and integration with a provider. A product may have evidence for one version while a consumer app with a similar name or interface has not been studied in the same way.
Software becomes management only with boundaries
Software becomes management through evidence, defined use and accountable follow-up, not through branding. Patients should expect the same clarity about benefits, risks and alternatives that they would ask of any other health intervention.
What separates a digital therapeutic from an app
The term digital therapeutic only means something if it maps onto a regulatory category, and it does. A product claiming to treat, prevent or manage a disease is software functioning as a medical device, and it has to be authorised for that specific indication. A product offering education, tracking, relaxation or general wellbeing is not, and it needs no review. Both can look identical on a phone screen.
So the first question about any product using the phrase is which of those it is, and for what. The FDA’s material on artificial intelligence and machine learning in software as a medical device, and its guidance on how to study and market a device, describe what an authorisation actually covers: a named condition, a defined patient population, and evidence measured against a reference standard. An authorisation for insomnia in adults is not an authorisation for anything else.
The evidence base is genuinely mixed by field rather than uniformly thin. Cognitive behavioural therapy for insomnia is the strongest example, because the underlying therapy is itself a first-line recommendation: the American College of Physicians guideline recommends that all adults with chronic insomnia receive CBT for insomnia as the initial treatment. A digital product delivering that has real therapy behind it. Elsewhere the picture is weaker, and the NIMH has noted how little effectiveness information exists across mental health technology generally.
The practical test for a reader is therefore not whether the word therapeutic appears, but whether you can find the authorisation, the indication and the trial. If all three exist, you are looking at a regulated treatment. If none do, you are looking at an app with a confident name.
